Navigation Links
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Date:10/10/2011

PRINCETON, N.J., Oct. 10, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of two treatment arms to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI-7977 to date provided the rationale for additional exploratory regimens in this setting.  The protocol amendment adds one arm exploring 12 weeks of PSI-7977 monotherapy in treatment naive patients with HCV genotype 1 (GT1), and one arm of PSI-7977 and ribavirin (RBV) in treatment-experienced patients with HCV genotype 2 (GT2) or genotype 3 (GT3).  In addition, the previously announced arm in HCV GT1 patients with a prior "null" response to an interferon (IFN) containing regimen, which was planned to assess PSI-7977/IFN/RBV, has been modified to an IFN-free 12-week regimen of PSI-7977/RBV.

"We look forward to reporting SVR12 results from Part 1 and interim data from the PSI-7977 monotherapy arm of ELECTRON on Sunday, November 6th, 2011 at the upcoming 2011 American Association for the Study of Liver Diseases (AASLD) annual meeting.  The preliminary results to be discussed at AASLD led us to expand the study to add an arm of PSI-7977 monotherapy for HCV GT1," said Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "We and others continue to explore the potential of PSI-7977 for IFN-free and monotherapy treatment regimens in a broader group of individuals living with HCV of all genotypes and regardless of their response to prior treatment."

In addition to previously announced interferon-free studies of PSI-7977 by Bristol Myers Squibb and Tibotec, The National Institute of Health (NIH) recently initiated an interferon-free 24 week study of PSI-7977 400mg QD with and without ribavirin, in 60 treat
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset to Present at Two Upcoming Conferences
2. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
3. Pharmasset Announces Two-for-One Forward Stock Split
4. Pharmasset to Present at Canaccord Genuity Growth Conference
5. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
6. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
9. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
10. Pharmasset to Webcast an Investor Event From the EASL Meeting
11. Pharmasset to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ... "Micro Market Monitor: North American Dermatology Diagnostic Devices ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic ... has resulted in fueling the overall demand of ... of these dermatology devices is to assist in ...
(Date:12/19/2014)... Dec. 18, 2014  RESMED INC. (NYSE: RMD ... of fiscal year 2015 results on Thursday, January 22, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... NetMotion Wireless, a leading provider of mobile productivity ... mobile Virtual Private Network (VPN) solution, Mobility XE, has ... hundreds of mobile workers for accessing wireless data and ... advance medical care, improve staff productivity and increase practice ...
... Sept. 7 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... conferences in September: Morgan Stanley Global Healthcare Conference ... York Stifel Nicolaus 2010 Healthcare ConferenceWednesday, September 15, at ... Conference Tuesday, September 21, at 9:00 a.m. ET in ...
Cached Medicine Technology:NetMotion Wireless Tapped by IDEXX Laboratories to Provide Secure Mobile Access to Field Personnel 2NetMotion Wireless Tapped by IDEXX Laboratories to Provide Secure Mobile Access to Field Personnel 3MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
(Date:12/19/2014)... Tampa, FL (PRWEB) December 19, 2014 ... Celliant Revitalizing Bedsheets are now available. Celliant, the ... in both sheets and pillowcases. , There are ... clinically proven additional circulation, increased oxygenation and balanced ... quality, faster healing and pain relief; enhanced athletic ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Silver Dollar ... official world record -- for the first time ever, Silver ... record book, Guinness World Records 2015, listing the park’s wood ... Roller Coaster. In additional awards announced this week, Silver Dollar ... Christmas Lights in the US,” USA Today’s 10Best awards for ...
(Date:12/19/2014)... Eufaula, Oklahoma, located just 9 miles ... state’s largest lake with more than 600 miles of ... a little more than 3,000 residents, hosted its annual ... 6th of December. , Featuring Santa, Christmas lights and ... on Main Street. Narconon Arrowhead’s parade float participated ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 An evening dress ... in a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has ... buy beautiful dresses in this great shopping platform. Customers ... to the staff's hard work, Discount-Dress.com has been accepted and ... a faster and easier shopping stage for clients. In order ...
(Date:12/19/2014)... 20, 2014 The print component of ... Business subscription of the Toronto Star, with a circulation ... 622,169. The digital component is distributed nationally through a ... top news sites and partner outlets. To explore the ... , The publication features an exclusive interview with ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2
... of existing cancer drugs? A preclinical study presented// at ... Therapeutics, in Prague, Czech Republic concluded that the answer ... treatment options for patients suffering from non-small cell lung ... form in the tissues of the lung. ...
... Toronto, Canada have found that only a small portion of ... the cells as believed earlier. // ,This is the ... found to be the source of the disease. Previously it ... supports the view - stem cells may be responsible for ...
... survey reveals that majority of doctors' fail in recognizing cow's ... in five GPs are not able to correctly diagnose the ... a risk to long-term health. ,The survey of ... Against Allergy and is sponsored by SHS International. The survey ...
... provincial livestock authorities to ensure all poultry farms are sanitized, ... left an indelible loss to the poultry industry. ... at the Department of Livestock Development confirmed that this move ... central provinces. Thailand has been free from bird flu for ...
... increasing numbers of childhood cancer patients survive into adulthood, ... in treatment, say senior cancer and fertility scientists. ... New Zealand are diagnosed with cancer every year, says ... Melbourne’s Royal Children’s Hospital. ,“About 75 ...
... meet diagnostic criteria for PTSD though males experience more ... a review of 25 years of research published by ... of psychological bulletin. ,The authors reviewed 290 ... is more at risk for potentially traumatic events (PTE) ...
Cached Medicine News:Health News:Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs 2Health News:Cancer Stem Cells Alone spread Cancer 2Health News:Majority Of Doctors Tend To Ignore Milk Allergy Cases In Babies 2Health News:Preserving Fertility for Child Cancer Patients 2Health News:Women Are More At Risk For PTSD Than Men 2Health News:Women Are More At Risk For PTSD Than Men 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: